Wednesday, February 12, 2020 7:12:49 AM
PR Newswire PR Newswire•February 12, 2020
SAN JOSE, Calif., Feb. 12, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that the research team lead by Dr. Jose Conejo-Garcia, Chair of the Department of Immunology at Moffitt Cancer Center, Anixa's development partner, has completed and validated the reformulation of the viral vector necessary for its CAR-T program.
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)
More
Last year, Anixa announced, that in order to improve the potential efficacy of its CAR-T therapy, it would reformulate the viral vector used to infect and engineer each individual patient's T-cells. The purpose was to increase the expression level of the Follicle Stimulating Hormone (FSH) on the engineered, autologous T-cells. With the successful viral vector reformulation, verification and validation, the new viral formulation is now being manufactured under Good Manufacturing Practice (GMP) conditions. This manufacturing process is expected to take approximately three months and Anixa and Moffitt remain on track to file the Investigational New Drug (IND) application in 2020.
CAR-T therapy requires the extraction and isolation of an individual's T-cells, followed by engineering these cells to enable them to more effectively kill cancer. These cells are then expanded and reinfused into the patient. Engineering these cells is performed by using a virus that itself has been engineered. The engineered virus initially infects the T-cells. Successive to infection, the virus induces the cellular machinery of the patient's T-cell to create on its surface, the "homing missiles" which in the case of Anixa's therapy are FSH molecules. It is expected that a T-cell with more FSH on the surface will be more effective at targeting ovarian cancer.
Dr. Amit Kumar, President and CEO of Anixa stated, "We are pleased to have completed this first milestone in our development program and remain confident in our previously stated development timeline."
"Our laboratory completed the reformulation of the viral vector, and we have demonstrated its ability to increase the concentration of FSH on the surface of transformed human T-cells. We expect the increased expression of FSH to provide better efficacy of our drug for ovarian cancer patients. We are looking forward to taking this therapy into the clinic as soon as possible," stated Dr. Conejo-Garcia.
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against a-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Recent ANIX News
- Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine • PR Newswire (US) • 09/24/2024 12:30:00 PM
- Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference • PR Newswire (US) • 09/18/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/06/2024 09:00:27 PM
- Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium • PR Newswire (US) • 09/03/2024 12:30:00 PM
- Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 08/26/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 04:42:57 PM
- Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting • PR Newswire (US) • 07/29/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 10:05:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 05:26:12 PM
- Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy • PR Newswire (US) • 07/23/2024 12:15:00 PM
- Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology • PR Newswire (US) • 07/17/2024 12:00:00 PM
- Anixa Biosciences Announces $5 Million Share Repurchase Program • PR Newswire (US) • 07/15/2024 12:30:00 PM
- Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 06/24/2024 12:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 01:22:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 01:56:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 03:18:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/10/2024 02:03:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 04:24:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 02:57:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/04/2024 09:00:57 PM
- Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial • PR Newswire (US) • 05/21/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 12:35:37 PM
- Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines • PR Newswire (US) • 05/08/2024 12:25:00 PM
- Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja • PR Newswire (US) • 05/06/2024 12:05:00 PM
- Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 • PR Newswire (US) • 04/30/2024 11:45:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM